BCL2 and diffuse large B-cell lymphoma: Our studies suggested that GNA13 loss-of-function mutations may serve as a biomarker for BCL2 inhibitor-mediated precision therapy of DLBCL and that GNA13 palmitoylation may be a potential target for combination therapy with BCL2 inhibitors to treat DLBCL with wild-type (WT) GNA13.